We have located links that may give you full text access.
Comparative Study
English Abstract
Journal Article
Review
[Indications and results of infliximab in Crohn's disease].
La Tunisie Médicale 2004 December
Infliximab is a chimeric monoclonal antibody to tumor necrosis factor a. Induction therapy with infliximab is indicated for treatment of refractory Crohn's disease and for reduction in the number of draining fistulas in fistulizing Crohn's disease. Indications for maintenance therapy with infliximab include maintenance of remission in active Crohn's disease who responded to initial induction therapy with infliximab and maintenance of fistula improvement who responded to initial therapy with infliximab. Side effects of infliximab are infusion reactions, immunogenicity, induction of DNA antibodies and infection complications including tuberculosis.
Full text links
Related Resources
Trending Papers
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis.Alimentary Pharmacology & Therapeutics 2024 March 26
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app